Letrozole

The label describes letrozole for adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer.

It is also described for extended adjuvant treatment after standard tamoxifen therapy, and as first and second line treatment of hormone receptor positive or unknown advanced breast cancer.

• Adjuvant treatment of early breast cancer
• Extended adjuvant treatment after tamoxifen
• First and second line treatment of advanced breast cancer

The label explains that some breast cancers are stimulated by oestrogen. After menopause, oestrogen is mainly made by the aromatase enzyme.

Letrozole blocks that enzyme, which lowers oestrogen levels.

This page covers the US label for letrozole tablets taken by mouth, with the dosing the label gives for adults.

This is label-level information, not personal advice. Indian pack labels may differ, and your prescriber's instruction always comes first.

For adults, the label describes one 2.5 mg tablet once daily, with or without food.

For cirrhosis or severe liver impairment, the label describes 2.5 mg every other day. No change is advised for mild to moderate liver impairment.

The best treatment length is described as unknown. In studies median treatment was about 5 years, and treatment stops at relapse or progression.

• 2.5 mg once daily
• With or without meals
• Every other day in cirrhosis or severe liver impairment
• Stop at relapse, as directed

The label lists pregnancy and known hypersensitivity as contraindications. A pregnancy test is advised for women who can become pregnant, along with effective contraception.

Bone mineral density and cholesterol monitoring should be considered. Fatigue, dizziness and sleepiness may occur, so caution with machinery is advised.

• Contraindicated in pregnancy
• Allergy to letrozole or ingredients
• Monitor bone density
• Monitor cholesterol
• Caution operating machinery

• Tamoxifen lowers letrozole levels
• No significant effect with cimetidine or warfarin
• Other anticancer agents: no experience
• Tamoxifen lowered letrozole blood levels by about 38% on average, though the label says effect was not impaired when given right after tamoxifen.
• Cimetidine and warfarin showed no clinically significant effect.
• There is no clinical experience with other anticancer agents.

No match in this label text. Ask your pharmacist about any medicine you take.

The label gives a storage range of 15 to 30 degrees C.

Follow the storage line on your own pack, and keep medicines out of the reach of children.

In the Drugs Rules schedules we checked, letrozole is listed under Schedule H (serial and rule: Schedule H, serial 280 (rules 65 and 97)). Schedule H medicines are sold only on a registered doctor's prescription.

Letrozole is on the National List of Essential Medicines 2022. Listed forms include: Tablet 2.5 mg (page 83); Powder for injection 3.75 mg (page 83).

NPPA lists ceiling prices for scheduled letrozole formulations. The table shows the rows we found. Check NPPA directly for the current list.

The Jan Aushadhi (PMBJP) list we checked has 1 product row that mention letrozole. We did not capture prices for them.

The banned fixed-dose combination list we checked has 1 entries that mention letrozole. This does not mean the single medicine is banned. Use our checker for a specific combination.

NPPA ceiling prices set the most a seller can charge per unit for the listed formulations, before local taxes. They are ceilings, not the price you will always pay.

Jan Aushadhi lists letrozole products including Letrozole Tablets IP 2.5mg 2.5mg. We have not shown a price for them. Check the pack and the seller for the actual price.